Basic Information
| Drug ID | DDPD01190 |
|
| Drug Name | Clindamycin | |
| Molecular Weight | 424.983 | |
| Molecular Formula | C18H33ClN2O5S | |
| CAS Number | 18323-44-9 | |
| SMILES | CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O | |
| External Links | ||
| DRUGBANK | DB01190 | |
| T3DB | T3D3497 | |
| PubChem Compound | 446598 | |
| PDR | 1019 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.16 | - | 2.16 | - | HANSCH,C ET AL. (1995) |
| Melting Point | 141.0 | ℃ | 141-143 | ℃ | Canadian labeling |
| pKa | 7.6 | - | 7.6 | - | Canadian labeling |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| AUC | 11000.0 | ng.h/ml | 11.0 | ug.h/ml | Oral single dose; | DRUGBANK | |
| Bioavailability | 90.0 | % | ~90 | % | PO, oral; | DRUGBANK | Bioavailability | 87.0 | % | ~87 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 2500.0 | ng/ml | 2.5 | ug/ml | PO, oral; | DRUGBANK | C Max | 17200.0 | ng/ml | 17.2±3.5 | mcg/ml | intravenous injection, IV; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | C Max | 2500.0 | ng/ml | 2.5 | mcg/ml | PO, oral; adults; | The Pharmacological Basis of Therapeutics |
| T Max | 0.75 | h | 0.75 | h | PO, oral; | DRUGBANK | |
| Clearance | 14.9 | L/h | 12.3-17.4 | L/h | Plasma clearance; | Hepatitis, Hep ↓ ; | DRUGBANK | Clearance | 0.28 | L/h/kg | 4.7±1.3 | ml/min/kg | Children → ; | The Pharmacological Basis of Therapeutics | Clearance | 0.27 | L/h/kg | 4.5 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 58.5 | L | 43-74 | L | DRUGBANK | Volume of Distribution | 1.1 | L/kg | 1.1±0.3 | L/kg | Children → ;RD, renal impairment, Renal disease，including uremia → ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.79 | L/kg | 0.79 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 3.0 | h | ~3 | h | adults; | DRUGBANK | Half-life | 2.5 | h | 2.5 | h | Children; | DRUGBANK | Half-life | 4.0 | h | ~4 | h | Elderly; | DRUGBANK | Half-life | 2.9 | h | 2.9±0.7 | h | Children → ;Preg, pregnant → ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ; | The Pharmacological Basis of Therapeutics | Half-life | 2.1 | h | 2.1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 2540.0 | mg/kg | 2540.0 | mg/kg | PO, oral; mouse; | DRUGBANK | Toxicity LD50 | 2190.0 | mg/kg | 2190.0 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK |
| Eliminate Route | 13.0 | % | 13 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 77.0 | % | 60-94 | % | DRUGBANK | Protein Binding | 93.6 | % | 93.6±0.2 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 20.0 | mg/kg/day | 20 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for neonates | 25.0 | mg/kg/day | 25 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for neonates | 27.0 | mg/kg/day | 9 | mg/kg/dose | PO, oral;intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for neonates | 21.0 | mg/kg/day | 7 | mg/kg/dose | PO, oral;intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for neonates | 15.0 | mg/kg/day | 5 | mg/kg/dose | PO, oral;intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for infants | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for infants | 25.0 | mg/kg/day | 25 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for infants | 40.0 | mg/kg/day | 40 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 2700.0 | mg/day | 2700 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 2400.0 | mg/day | 2400 | mg/day | IM,intramuscular injection | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 25.0 | mg/kg/day | 25 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 40.0 | mg/kg/day | 40 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 1800.0 | mg/day | 1800 | mg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 2.0 | application/day | 2 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 1.0 | application/day | 1 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 2700.0 | mg/day | 2700 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 2400.0 | mg/day | 2400 | mg/day | IM,intramuscular injection | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 25.0 | mg/kg/day | 25 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 40.0 | mg/kg/day | 40 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for children | 1800.0 | mg/day | 1800 | mg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 2700.0 | mg/day | 2700 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 2400.0 | mg/day | 2400 | mg/day | IM,intramuscular injection | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 25.0 | mg/kg/day | 25 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 40.0 | mg/kg/day | 40 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1800.0 | mg/day | 1800 | mg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 2.0 | application/day | 2 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | applicatorful/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | applicatorful/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | ovule/day | 1 | ovule/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 40.0 | mg/kg/day | 40 | mg/kg/day | intravenous injection, IV;IM,intramuscular injection; | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 2700.0 | mg/day | 2700 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 2400.0 | mg/day | 2400 | mg/day | IM,intramuscular injection | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 25.0 | mg/kg/day | 25 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 40.0 | mg/kg/day | 40 | mg/kg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1800.0 | mg/day | 1800 | mg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 2.0 | application/day | 2 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | applicatorful/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | applicatorful/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 1.0 | ovule/day | 1 | ovule/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adolescents | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 2700.0 | mg/day | 2700 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 4800.0 | mg/day | 4800 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 2400.0 | mg/day | 2400 | mg/day | IM,intramuscular injection | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 1800.0 | mg/day | 1800 | mg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 2.0 | appLication/day | 2 | appLication/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 1.0 | appLication/day | 1 | appLication/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 1.0 | appLicatorfuL/day | 1 | appLicatorfuL/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 1.0 | appLicatorfuL/day | 1 | appLicatorfuL/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 1.0 | ovuLe/day | 1 | ovuLe/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 2700.0 | mg/day | 2700 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 4800.0 | mg/day | 4800 | mg/day | intravenous injection, IV | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 2400.0 | mg/day | 2400 | mg/day | IM,intramuscular injection | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 1800.0 | mg/day | 1800 | mg/day | PO, oral | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 2.0 | application/day | 2 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 1.0 | application/day | 1 | application/day | skin/dermal | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 1.0 | applicatorful/day | 1 | applicatorful/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 1.0 | applicatorful/day | 1 | applicatorful/day | Vaginal Administration; once | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 5000.0 | mg/day | 5 | g/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 1.0 | ovule/day | 1 | ovule/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | Vaginal Administration | Cleocin T | clindamycin phosphate | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1